Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypersensitivity reactions associated with oxaliplatin.

M Wasif Saif1

  • 1Yale University School of Medicine, Section of Medical Oncology, 333 Cedar Street, FMP 116, New Haven, CT 06520, USA. wasif.saif@yale.edu

Expert Opinion on Drug Safety
|August 16, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

COVID-19 Disease and SARS-CoV-2 Vaccination in Patients with Cancer.

Archives of pharmacology and therapeutics·2021
Same author

Neoadjuvant Therapy (NAT) in Localized Pancreatic Cancer: Should We Do It and What Should We Do?

Journal of cellular signaling·2021
Same author

The Role of Olaparib in Metastatic Pancreatic Cancer.

Cancer medicine journal·2021
Same author

Association of Pharmacogenetics With Adverse Events of Fluorouracil/Capecitabine in Patients With Cancer.

JCO oncology practice·2021
Same author

Safety and Efficacy of s-MOX Regimen in Patients with Colorectal Cancer Who Developed Cardiotoxicity Following Fluoropyrimidine Administration: A Case Series.

Archives of medical case reports·2020
Same author

Lessons Learnt from COVID-19: How Can We Prepare for Another Pandemic?

Archives of cancer biology and therapy·2020

Hypersensitivity reactions (HSRs) to oxaliplatin occur in about 12% of colorectal cancer patients. Management strategies like desensitization are being explored for this increasing toxicity.

Area of Science:

  • Oncology
  • Clinical Pharmacology

Background:

  • Oxaliplatin is a key chemotherapy agent for colorectal cancer (CRC).
  • Hypersensitivity reactions (HSRs) to oxaliplatin affect approximately 12% of patients, with 1-2% experiencing severe reactions.
  • The incidence of HSRs is rising due to increased clinical use of oxaliplatin.

Purpose of the Study:

  • To discuss the incidence, clinical presentation, pathogenesis, risk factors, and management strategies for oxaliplatin-induced HSRs.
  • To highlight the importance of understanding oxaliplatin toxicity as its use expands to various solid malignancies.

Main Methods:

  • Review of existing literature on oxaliplatin HSRs.
  • Discussion of reported management strategies including infusion rate modification, pharmacologic interventions, and desensitization protocols.

Related Experiment Videos

  • Exploration of recent alternative approaches like subcutaneous adrenaline.

    • Main Results:

    • HSRs manifest with diverse symptoms including flushing, rash, dyspnea, and potentially anaphylactic shock.
    • No definitive preventative or treatment protocols exist, but strategies like desensitization show promise in case studies.
    • Large-scale validation of desensitization strategies is lacking.

    Conclusions:

    • Oxaliplatin HSRs are a significant concern, necessitating awareness and further research into effective management.
    • Desensitization protocols, while promising, require larger studies for validation.
    • Continued investigation into managing HSRs is crucial for optimizing CRC and other solid malignancy treatment.